A Japanese health ministry proposal to impose steeper price cuts on certain medicines deemed to carry poor cost-effectiveness profiles cleared…
HOME > TOP STORIES
TOP STORIES
-
REGULATORY Commodity Prices Are Rising, That’s Why Full Drug Re-Pricing Needed in 2023: MOF Official
October 25, 2022
-
REGULATORY Moderna’s BA.4/5 COVID Jab Up for PAFSC Review on Oct. 31
October 25, 2022
-
BUSINESS Genmab to Branch Out into 2nd Disease Area beyond Cancer, Specifics to Be Unveiled Next Year: CEO
October 24, 2022
-
ORGANIZATION Over 80% of Wholesaler Reps Say Shipment Adjustments Take Up Most of Their Time: Survey
October 21, 2022
-
REGULATORY With Shortened Interval, Omicron Booster Likely to Cover 18 Million More People by Month-End
October 21, 2022
-
BUSINESS Kyowa Kirin Assigns Bone Metabolism Specialists to Promote Crysvita in Japan
October 20, 2022
-
BUSINESS Sumitomo Aiming to Take the Lead in Developing Universal Flu Vaccines
October 19, 2022
-
BUSINESS Bayer to Distribute Xarelto Tablets 2.5 mg via Single Wholesaler
October 18, 2022
-
REGULATORY Health Ministry Research Team to Vet Recall Rules to Address Supply Disruptions
October 17, 2022
-
BUSINESS Fujifilm Ditches Avigan COVID-19 Program, Pulls Submission in Japan
October 17, 2022
-
BUSINESS Fertility Drugs Face Supply Woes as Demand Spikes on Health Coverage
October 14, 2022
-
REGULATORY Govt Eyes Designation of Cefazolin, Other Antibiotics as Key Resources
October 14, 2022
-
REGULATORY MHLW Expert Panel Sorts Out Discussion Points for Full Debate; Focus on Innovation, Stable Supply, and Margins
October 13, 2022
-
ACADEMIA Japan Expert Sees Lecanemab Initially Treating Only a Few Tens of Thousands of Patients with Immature Care Setup
October 12, 2022
-
BUSINESS Kyushu Univ. Spinoff Aims to File NK-Like Cells in 2025, Eyes Combo with Checkpoint Drugs
October 11, 2022
-
REGULATORY Japan to Roll Out BA.4/5 Omicron Boosters on Oct. 13, Inoculations for 6 Months to 4 Years from Oct. 24
October 11, 2022
-
REGULATORY MHLW Panel to Discuss Shortening of COVID Booster Interval
October 11, 2022
-
ORGANIZATION EFPIA Chief Prods Japan on Mutual Trial Data Recognition, Cooperation to Boost Attractiveness to Rival US, China
October 7, 2022
-
REGULATORY Chuikyo Kicks Off Debate on FY2023 Off-Year Drug Price Revision
October 6, 2022
-
BUSINESS Moderna Files BA.4/5-Tailored COVID-19 Vaccine in Japan
October 5, 2022
ページ
A Japanese drug pricing panel on November 11 discussed ways to respond to the US most-favored-nation (MFN) policy, with healthcare…
On paper, things should be looking up for Japan’s pharmaceutical wholesalers. Industry expectations are mounting that the average gap between NHI and market prices will narrow further in FY2026 from the previous year’s record low of 4.8%.A shrinking gap should…
Japan is set to add 16 new drugs to its NHI reimbursement price list on November 13, including a subcutaneous…
Tariffs have been a defining feature of US trade policy under President Donald Trump’s second administration. Since Trump unveiled his “reciprocal” tariff policy in April 2025, the landscape has shifted repeatedly.In February 2026, the US Supreme Court invalidated tariffs imposed…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…